Bicocca Open Archive

Logo unimib boa
LISSONI, ANDREA ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.203
AS - Asia 6.460
EU - Europa 5.259
SA - Sud America 1.065
Continente sconosciuto - Info sul continente non disponibili 418
AF - Africa 180
OC - Oceania 13
Totale 27.598
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.638
SG - Singapore 2.272
CN - Cina 1.425
IT - Italia 1.368
HK - Hong Kong 961
BR - Brasile 795
RU - Federazione Russa 782
VN - Vietnam 686
SE - Svezia 526
UA - Ucraina 516
DE - Germania 502
IE - Irlanda 474
CA - Canada 439
GB - Regno Unito 285
FR - Francia 224
IN - India 214
BD - Bangladesh 208
FI - Finlandia 150
AT - Austria 135
AR - Argentina 106
KR - Corea 105
TR - Turchia 81
NL - Olanda 63
ZA - Sudafrica 63
IQ - Iraq 62
ID - Indonesia 61
PK - Pakistan 61
MX - Messico 58
JP - Giappone 55
PH - Filippine 49
DK - Danimarca 45
ES - Italia 44
CO - Colombia 40
EC - Ecuador 39
PL - Polonia 39
SA - Arabia Saudita 35
MA - Marocco 31
VE - Venezuela 28
BE - Belgio 24
UZ - Uzbekistan 24
MY - Malesia 19
JO - Giordania 18
KE - Kenya 17
PY - Paraguay 16
AE - Emirati Arabi Uniti 15
JM - Giamaica 15
CH - Svizzera 14
IR - Iran 14
CL - Cile 13
TH - Thailandia 13
TN - Tunisia 13
UY - Uruguay 13
CR - Costa Rica 12
EG - Egitto 12
AU - Australia 11
IL - Israele 10
RO - Romania 10
TW - Taiwan 10
ET - Etiopia 9
EU - Europa 9
HN - Honduras 9
AL - Albania 8
NP - Nepal 8
PE - Perù 8
SN - Senegal 8
BO - Bolivia 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
LT - Lituania 7
PS - Palestinian Territory 7
LB - Libano 6
NI - Nicaragua 6
RS - Serbia 6
AZ - Azerbaigian 5
OM - Oman 5
PA - Panama 5
CZ - Repubblica Ceca 4
EE - Estonia 4
MN - Mongolia 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
AO - Angola 3
BG - Bulgaria 3
BY - Bielorussia 3
GR - Grecia 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BN - Brunei Darussalam 2
BZ - Belize 2
CI - Costa d'Avorio 2
CM - Camerun 2
CY - Cipro 2
GE - Georgia 2
GT - Guatemala 2
Totale 27.154
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.846
Ashburn 1.282
Singapore 1.262
Woodbridge 1.188
Hong Kong 937
San Jose 692
Houston 684
Fairfield 677
Jacksonville 524
Dublin 441
Chandler 414
Wilmington 402
Milan 353
Dearborn 335
New York 321
Seattle 302
Frankfurt am Main 297
Santa Clara 259
Cambridge 255
Toronto 237
Princeton 220
Council Bluffs 215
Chicago 214
The Dalles 214
Los Angeles 195
Ho Chi Minh City 185
Beijing 184
Dallas 168
Hanoi 157
Hefei 134
Vienna 122
Rome 110
Lauterbourg 109
Nanjing 109
Altamura 106
Lawrence 104
Shanghai 93
Seoul 92
Lachine 91
Boardman 81
Moscow 77
São Paulo 73
Buffalo 65
Fremont 49
Guangzhou 49
San Diego 48
Andover 46
Helsinki 44
Washington 42
Ottawa 41
London 39
Nanchang 39
Rio de Janeiro 38
Hebei 34
Munich 33
Phoenix 33
Orem 32
Changsha 31
Tokyo 31
Tianjin 30
Warsaw 30
Atlanta 29
Brooklyn 29
Da Nang 29
Jakarta 29
Jiaxing 29
Shenyang 29
Detroit 28
Figino 28
Columbus 27
Baghdad 25
Johannesburg 25
Salt Lake City 25
Montreal 24
Chennai 23
Naples 23
Brussels 22
Huizen 22
Kunming 22
Nuremberg 22
Denver 21
Lahore 21
Philadelphia 21
Pune 21
San Francisco 21
Tashkent 20
Falls Church 19
Bologna 18
Manchester 18
Norwalk 18
Ankara 17
Hangzhou 17
Lissone 17
Quito 17
Amsterdam 16
Brasília 16
Miami 16
Amman 15
Belo Horizonte 15
Haiphong 15
Totale 17.364
Salva come PNG Salva come JPEG
Nome #
High-dose epirubicin in patients with advanced or recurrent uterine sarcoma 587
Oncologic and fertility impact of surgical approach for borderline ovarian tumours treated with fertility sparing surgery 553
Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms 448
Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (Stumps) revealed similarities and differences with leiomyomas and leiomyosarcomas 430
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 428
Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production 412
Potential role of BCL2 in the recurrence of uterine smooth muscle tumors of uncertain malignant potential 402
Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers 382
Clinical outcome of patients with malignant tumors associated with mature cystic teratomas of the ovary: A retrospective multicenter Italian study 377
From Conventional Radiotracer Tc-99m with Blue Dye to Indocyanine Green Fluorescence: A Comparison of Methods Towards Optimization of Sentinel Lymph Node Mapping in Early Stage Cervical Cancer for a Laparoscopic Approach 356
Randomized phase III clinical trial evaluating weekly cisplatin for advanced epithelial ovarian cancer 350
The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis 342
OC13. 02: Reproducibility of IETA terms in describing endometrial pathology 336
Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial 316
Imact of bevacizumab-containing primary treatment on outcome of recurrent ovarian cancer: An Italian study 312
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial 309
Long-term clinical benefits of neoadjuvant chemotherapy in women with locally advanced cervical cancer: Validity of pathological response as surrogate endpoint of survival 301
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer 286
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study 285
Synchronous early-stage endometrial and ovarian cancer 285
Dose-dense neoadjuvant chemotherapy with paclitaxel and carboplatin in cervical cancer: Efficacy on pathological response 282
Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors 280
Early and short-term complications after US-guided puncture of gynecologic lesions: evaluation after 1,000 consecutive cases 280
Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group 279
Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy 278
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 275
Fertility outcomes in stage I ovarian immature teratomas 275
Uterine leiomyosarcoma: analysis of treatment failures and survival 274
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial 272
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale 267
Primary malignant vaginal melanoma treated with adriamycin and ifosfamide: a case report and literature review 263
Sentinel lymph node detection in endometrial cancer: hysteroscopic peritumoral versus cervical injection 260
A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer 259
Adjuvant sequential chemo and radiotherapy improves the oncological outcome in high risk endometrial cancer 259
Endometriomas: Their ultrasound characteristics 248
Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma 246
A phase II randomised clinical trial comparing cisplatin, paclitaxel and ifosfamide with cisplatin, paclitaxel and epirubicin in newly diagnosed advanced epithelial ovarian cancer: long-term survival analysis 244
Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience 240
Pre-operative morphological and colour Doppler features of borderline ovarian tumours 240
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 238
Endometrial stromal sarcoma: analysis of treatment failures and survival 236
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas 234
Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study 232
Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients 231
Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray-scale and Doppler ultrasound findings: logistic regression models do not help 230
Ultrasound characteristics of endometrial hyperplasia described using IETA terms 230
Grading of chemotherapy-induced peripheral neurotoxicity using the Total Neuropathy Scale 228
A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study 228
Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells 227
Brachytherapy for isolated vaginal recurrences from endometrial carcinoma 227
Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy 227
Prospective multicenter study on CA 125 in postmenopausal pelvic masses 225
Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients 224
External validation of diagnostic models to estimate the risk of malignancy in adnexal masses 221
Machine Learning Application Identifies Germline Markers of Hypertension in Patients With Ovarian Cancer Treated With Carboplatin, Taxane, and Bevacizumab 217
Imaging in gynecological disease (7): clinical and ultrasound features of Brenner tumors of the ovary 216
Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy 215
Ovarian cancer prediction in adnexal masses using ultrasound based logistic regression models: a temporal and external validation study by the IOTA group 213
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes 212
Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma 212
Prospective multicenter study on the clinical utility of CA 72.4 in post-menopausal patients with pelvic mass 212
Safety of transvaginal fine needle puncture of gynecologic masses: a report after 500 consecutive procedures 212
Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies 210
Optimal treatment of early-stage ovarian cancer 209
Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis 208
Role of puncture and aspiration in expectant management of simple ovarian cysts: a randomised study 207
Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study 206
Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: An Italian multicentric retrospective analysis 203
Tumor volume as risk factor for nodal diffusion in endometrial cancer 202
Antiemetic efficacy of granisetron in patients with gynecological malignancies 201
Ultrasound in the follow-up of young patients with malignant ovarian tumors after conservative surgery 200
Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses 200
Color Doppler ultrasound in the preoperative assessment of adnexal masses 200
International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer 200
Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice 199
Primary carcinoma of the fallopian tube. A retrospective analysis of 47 patients 197
Effectiveness of autologous blood transfusion in patients undergoing radical hysterectomy 195
Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: results from the ILIADE randomized study 194
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients 193
Ifosfamide in the treatment of malignant epithelial ovarian tumors 192
Changes in the management and outcome of central nervous system involvement from ovarian cancer since 1994 192
Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells 191
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial 186
The prognostic relevance of histological type in uterine sarcomas: A cooperation task force (CTF) multivariate analysis of 249 cases 182
A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA-125: a multicenter observational study 181
Brain metastases from endometrial carcinoma 181
Clinically oriented three-step strategy for assessment of adnexal pathology 181
Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma 181
Unilocular adnexal cysts with papillary projections but no other solid components: Is there a diagnostic method that can classify them reliably as benign or malignant before surgery? 179
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer 178
Second-look laparotomy in the management of fallopian tube carcinoma 177
Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study 174
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas 173
Fertility-sparing surgery in uterine leiomyosarcoma 170
Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial 169
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer 168
Alpha-fetoprotein in the management of germ cell tumors of the ovary 166
Total neuropathy scale items as early predictors of chemotherapy‐induced peripheral neurotoxicity 160
Response to chemotherapy and Clinical Outcome of Patients with recurrent epithelial ovarian cancer after PARP inhibitor maintenance treatment: a Multicenter retrospective italina Study 158
Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer 156
Totale 24.784
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.919
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.919
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.020 0 0 81 112 105 94 55 91 56 85 108 233
2022/20231.892 256 577 134 137 182 297 13 90 125 17 31 33
2023/20241.380 38 43 77 73 181 353 264 33 133 39 19 127
2024/20253.730 195 512 192 196 303 144 268 125 329 517 318 631
2025/20269.492 860 594 763 891 1.016 511 1.147 614 823 917 567 789
2026/20271.396 461 469 466 0 0 0 0 0 0 0 0 0
Totale 27.598